Welcome to our dedicated page for Argenx Se news (Ticker: ARGX), a resource for investors and traders seeking the latest updates and insights on Argenx Se stock.
argenx SE reports developments as a global immunology company developing and commercializing antibody-based medicines for severe autoimmune diseases. Its updates center on VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), including approved use in adult generalized myasthenia gravis and clinical and regulatory work across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
Recurring announcements also cover product sales, business updates, presentations of neuromuscular data, and pipeline progress for candidates such as empasiprubart, a monoclonal antibody targeting complement factor C2, and adimanebart. Governance items include annual general meeting results, board appointments, and leadership transitions for the Euronext- and Nasdaq-listed foreign issuer.
argenx announced the continuation of patient enrollment in the ADHERE trial for efgartigimod in treating chronic inflammatory demyelinating polyneuropathy (CIDP). The independent data monitoring committee confirmed this decision after interim efficacy and safety assessments surpassed predefined thresholds. The aim is to enroll approximately 130 patients to support the drug's potential registration. The company underscores the clinical proof-of-concept for efgartigimod in CIDP, enhancing its portfolio of treatments for autoimmune diseases.
On November 17, 2020, argenx (ARGX) launched a docuseries titled A Mystery to Me, focusing on Myasthenia Gravis (MG), a rare autoimmune disease. The series aims to raise awareness of MG by showcasing the lives of three individuals affected by it. The docuseries is produced by Sarofsky Productions and will be available on MG-United.com following its debut. CEO Tim Van Hauwermeiren emphasized the importance of listening to MG patients to better understand their challenges. The MG Foundation highlighted the connection this series could foster within the community, particularly during the COVID-19 pandemic.
argenx (Euronext & Nasdaq: ARGX), a global immunology company, will host a conference call on October 22, 2020, at 2:30 p.m. CET (8:30 a.m. ET) to discuss its Q3 2020 financial results and provide a business update. The live call can be accessed via the Investors section of their website, with a replay available for one year. argenx focuses on severe autoimmune diseases and cancer treatments, evaluating efgartigimod and cusatuzumab in collaboration with Janssen. The company aims to translate immunology breakthroughs into innovative antibody-based medicines.
argenx, a global immunology company, announced new partnerships with Chugai and the Clayton Foundation to enhance its antibody engineering capabilities. This expansion includes access to advanced technologies for developing first-in-class medicines targeting severe autoimmune diseases and cancers. Additionally, argenx is extending its collaboration with Halozyme, securing subcutaneous delivery options for three more product candidates. These strategies aim to strengthen argenx's innovative pipeline and solidify its leadership in immunology.
On October 5, 2020, argenx (ARGX) announced new findings from its Phase 3 ADAPT trial for efgartigimod, a treatment for generalized myasthenia gravis (gMG). The results, presented at the MGFA 2020 Virtual Scientific Session, demonstrated significant improvements in patients' daily functioning and safety comparable to placebo. Notably, over 55% of treated patients showed substantial improvements in key scoring metrics. The company plans to submit a Biologics License Application to the FDA by the end of 2020, aiming for commercialization in 2021.
On September 2, 2020, argenx (Euronext & Nasdaq: ARGX) announced participation in key healthcare conferences. Management will conduct a fireside chat at the Baird Global Healthcare Conference on September 9 at 12:15 p.m. ET, followed by the Morgan Stanley Global Healthcare Conference on September 14 at 1:30 p.m. ET and BofA Global Healthcare Conference on September 17 at 10:50 a.m. BST. Lastly, a panel will take place at the Stifel Immunology & Inflammation Summit on October 1 at 11:00 a.m. ET. More details are available on the company’s website.